We are live on ! Find out more
KRYS icon

Krystal Biotech
KRYS

154 hedge funds and large institutions have $1.62B invested in Krystal Biotech in 2022 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 62 increasing their positions, 50 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

80% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 10

24% more repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 50

12% more capital invested

Capital invested by funds: $1.45B → $1.62B (+$175M)

4% more funds holding

Funds holding: 148 → 154 (+6)

0.06% more ownership

Funds ownership: 81.12% → 81.18% (+0.06%)

0% more funds holding in top 10

Funds holding in top 10: 5 → 5 (0)

73% less call options, than puts

Call options by funds: $5.68M | Put options by funds: $21.4M

Holders
154
Holders Change
+6
Holders Change %
+4.05%
% of All Funds
2.48%
Holding in Top 10
5
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
18
Increased
62
Reduced
50
Closed
10
Calls
$5.68M
Puts
$21.4M
Net Calls
-$15.7M
Net Calls Change
-$9.94M

Top Buyers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
+$10M
2
BlackRock
BlackRock
New York
+$9.97M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$6.83M
4
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$4.9M
5
NIP
Nicholas Investment Partners
California
+$3.34M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$52.1M
2
BBA
Baker Bros. Advisors
New York
-$8.87M
3
AG
Artal Group
Luxembourg
-$7.42M
4
PAMS
Pictet Asset Management (Switzerland)
Switzerland
-$7.29M
5
N
Nuveen
North Carolina
-$2.07M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$12.7M +$322K +4,344 +3%
Goldman Sachs
27
Goldman Sachs
New York
$11.7M +$387K +5,216 +4%
IHAM
28
Integral Health Asset Management
New York
$9.11M +$1.86M +25,000 +28%
SST
29
S Squared Technology
New York
$8.57M – – –
ECM
30
ExodusPoint Capital Management
New York
$8.38M +$3.04M +40,975 +63%
Handelsbanken Fonder
31
Handelsbanken Fonder
Sweden
$8.33M +$22.3K +300 +0.3%
RCMNY
32
Rubric Capital Management (New York)
New York
$7.34M – – –
Bank of New York Mellon
33
Bank of New York Mellon
New York
$6.5M -$200K -2,696 -3%
Verition Fund Management
34
Verition Fund Management
Connecticut
$6.38M +$958K +12,909 +19%
Bank of America
35
Bank of America
North Carolina
$5.39M +$1.98M +26,679 +64%
Morgan Stanley
36
Morgan Stanley
New York
$5.23M +$1.39M +18,738 +40%
VOYA Investment Management
37
VOYA Investment Management
Georgia
$4.96M -$117K -1,577 -2%
Rafferty Asset Management
38
Rafferty Asset Management
New York
$4.88M +$695K +9,369 +18%
SCM
39
Silverarc Capital Management
Massachusetts
$4.64M +$140K +1,890 +3%
N
40
Nuveen
North Carolina
$4.55M -$2.07M -27,913 -33%
MPAM
41
Monarch Partners Asset Management
Massachusetts
$4.27M +$550K +7,411 +16%
Citadel Advisors
42
Citadel Advisors
Florida
$4.17M +$3.26M +43,938 +503%
HWAM
43
Hennion & Walsh Asset Management
New Jersey
$3.58M +$337K +4,547 +11%
IBT
44
International Biotechnology Trust
United Kingdom
$3.56M – – –
Swiss National Bank
45
Swiss National Bank
Switzerland
$3.44M +$59.4K +800 +2%
UBS Group
46
UBS Group
Switzerland
$3.38M +$3.15M +42,459 +25,890%
SG Americas Securities
47
SG Americas Securities
New York
$3.07M +$2.7M +36,434 +1,557%
Carson Wealth (CWM LLC)
48
Carson Wealth (CWM LLC)
Nebraska
$2.94M -$464K -6,254 -14%
Barclays
49
Barclays
United Kingdom
$2.88M +$239K +3,217 +10%
EI
50
EAM Investors
California
$2.63M -$14.4K -194 -0.6%
1
2
3 4 5

KRYS Hedge Fund Activity: Q4 2022 in Review

154 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2022, worth a combined $1.62B — up 12% from $1.45B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new KRYS positions and 10 closed out — a net gain of 8 holders — while 62 added to existing stakes and 50 trimmed.

The largest buyer was Avoro Capital Advisors, adding an estimated $10M. The largest seller was Point72 Asset Management, cutting an estimated $52.1M.

  • 154 institutional investors held Krystal Biotech (KRYS) as of Q4 2022, up from 148 in Q3 2022.
  • Funds reported $1.62B of Krystal Biotech stock for Q4 2022, up 12% quarter-over-quarter.
  • 18 funds opened new Krystal Biotech positions in Q4 2022 and 10 closed out, a net change of +8 holders.
  • The largest Krystal Biotech buyer in Q4 2022 was Avoro Capital Advisors, an estimated $10M added.
  • The largest Krystal Biotech seller in Q4 2022 was Point72 Asset Management, an estimated $52.1M sold.

Based on aggregated 13F filings for Q4 2022.